This case report explores the clinical implications of partial BRG-1 deficiency in lung cancer, highlighting the importance of comprehensive molecular profiling and the potential role of combined therapeutic strategies, including immunotherapy. This evidence concerns the gene SMARCA4 and lung cancer.